Cambridge Investment Research Advisors
SRPT icon

Cambridge Investment Research Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Cambridge Investment Research Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,387
Closed -$408K – 3752
2025
Q1 		$408K Buy
6,387
+358
+6% +$37.7K ﹤0.01% 2623
2024
Q4 		$733K Buy
6,029
+632
+12% +$77.5K ﹤0.01% 2111
2024
Q3 		$674K Sell
5,397
-934
-15% -$129K ﹤0.01% 2173
2024
Q2 		$1M Buy
6,331
+120
+2% +$15.4K ﹤0.01% 1778
2024
Q1 		$804K Buy
6,211
+3,267
+111% +$400K ﹤0.01% 1884
2023
Q4 		$284K Buy
2,944
+154
+6% +$14.8K ﹤0.01% 2636
2023
Q3 		$338K Buy
2,790
+2
+0.1% +$226 ﹤0.01% 2414
2023
Q2 		$319K Buy
2,788
+3
+0.1% +$387 ﹤0.01% 2480
2023
Q1 		$384K Buy
2,785
+1,141
+69% +$148K ﹤0.01% 2281
2022
Q4 		$213K Sell
1,644
-467
-22% -$54.1K ﹤0.01% 2706
2022
Q3 		$233K Buy
+2,111
New +$213K ﹤0.01% 2585
2022
Q1 		– Sell
-3,265
Closed -$294K – 3303
2021
Q4 		$294K Sell
3,265
-865
-21% -$73.9K ﹤0.01% 2540
2021
Q3 		$382K Sell
4,130
-1,201
-23% -$92.5K ﹤0.01% 2259
2021
Q2 		$414K Buy
5,331
+365
+7% +$27.7K ﹤0.01% 2209
2021
Q1 		$370K Buy
4,966
+1,580
+47% +$146K ﹤0.01% 2133
2020
Q4 		$577K Sell
3,386
-717
-17% -$106K ﹤0.01% 1677
2020
Q3 		$576K Sell
4,103
-99
-2% -$15K ﹤0.01% 1522
2020
Q2 		$674K Sell
4,202
-863
-17% -$117K 0.01% 1369
2020
Q1 		$495K Buy
5,065
+400
+9% +$45.7K ﹤0.01% 1370
2019
Q4 		$602K Buy
4,665
+86
+2% +$8.68K ﹤0.01% 1463
2019
Q3 		$345K Sell
4,579
-82
-2% -$9.68K ﹤0.01% 1733
2019
Q2 		$708K Hold
4,661
– – 0.01% 1231
2019
Q1 		$556K Buy
4,661
+495
+12% +$63.6K 0.01% 1414
2018
Q4 		$455K Sell
4,166
-2,227
-35% -$279K 0.01% 1378
2018
Q3 		$1.03M Buy
6,393
+2,596
+68% +$355K 0.01% 1008
2018
Q2 		$502K Sell
3,797
-6,754
-64% -$637K 0.01% 1396
2018
Q1 		$782K Buy
10,551
+5,912
+127% +$394K 0.01% 1073
2017
Q4 		$258K Sell
4,639
-1,011
-18% -$53.6K ﹤0.01% 1753
2017
Q3 		$256K Buy
+5,650
New +$226K ﹤0.01% 1663

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Cambridge Investment Research Advisors's SRPT Position: Q2 2025 in Review

Cambridge Investment Research Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 6,387 shares — an estimated $408K sold.

Cambridge Investment Research Advisors first reported a position in SRPT in Q3 2017 and held it in 29 quarters. The position peaked at $1.03M in Q3 2018. 363 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Cambridge Investment Research Advisors reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 6,387 Sarepta Therapeutics shares in Q2 2025, an estimated $408K.
  • Cambridge Investment Research Advisors first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 29 quarters.
  • Cambridge Investment Research Advisors's Sarepta Therapeutics position peaked at $1.03M in Q3 2018.
  • 363 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2025, filed 31 Jul 2025.